Structure-Based Virtual Screening and Molecular Dynamics Simulation to Identify Potential SARS-CoV-2 Spike Receptor Inhibitors from Natural Compound Database

被引:0
作者
Arkadeep Sarkar
Debanjan Sen
Ashutosh Sharma
Ravi Kumar Muttineni
Sudhan Debnath
机构
[1] BCDA College of Pharmacy & Technology,Department of Pharmacy
[2] Tecnologico de Monterrey,School of Engineering and Sciences
[3] Campus Queretaro,Department of Chemistry
[4] Immunocure Discovery Solution Pvt. ltd,undefined
[5] M. B. B. College,undefined
来源
Pharmaceutical Chemistry Journal | 2021年 / 55卷
关键词
MolPort database; spike receptor; ADME filtration; molecular docking; molecular dynamics;
D O I
暂无
中图分类号
学科分类号
摘要
The outbreak of respiratory disease, COVID-19 caused by SARS-CoV-2 has now been spread globally and the number of new infections is rising every moment. There are no specific medications that are currently available to combat the disease. The spike receptor of SARS-CoV-2 facilitates the viral entry into a host cell and initiation of infection. Targeting the viral entry at the initial stage has a better advantage than inhibiting it in later stages of the viral life cycle. This study deals with identification of the potential natural molecule or its derivatives from MolPort Databank as SARS-CoV-2 spike receptor inhibitors using structure-based virtual screening followed by molecular dynamics simulation. On the basis of ADME properties, docking score, MMGBSAbinding energy, 150 ns molecular docking studies, and final molecular dynamics analysis, two natural compounds – 3 (MolPort-002-535-004) docking score –9.10 kcal mol-1 and 4 (MolPort-005-910-183) docking score –8.5 kcal mol-1, are selected as potential in-silico spike receptor inhibitors. Both hits are commercially available and can be further used for in-vitro and in-vivo studies. Findings of this study can facilitate rational drug design against SARS-CoV-2 spike receptor.
引用
收藏
页码:441 / 453
页数:12
相关论文
共 75 条
  • [1] Durojaiye AB(2020)undefined Struct. Dyn. 2020 1-8
  • [2] Clarke JRD(2015)undefined Antiviral Res. 116 76-84
  • [3] Stamatiades GA(2020)undefined Indian J. Pharmacol. 52 56-65
  • [4] Wang C(2019)undefined Virol. J. 16 1-22
  • [5] Biomol J(2020)undefined Front. Immunol. 11 1662-620
  • [6] Zhou Y(2020)undefined Cell. Mol. Immunol. 17 613-331
  • [7] Prajapat M(2020)undefined ACS Cent. Sci. 6 315-582
  • [8] Schoeman D(2020)undefined J. Med. Chem. 63 12256-285
  • [9] Fielding BC(2020)undefined Ann. Intern. Med. 172 577-178
  • [10] Guihot A(2020)undefined Nature 583 282-280